(PRESS RELEASE) VEVEY, 21-Dec-2020 — /EuropaWire/ — Nestlé Health Science Company, Aimmune Therapeutics announces that PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)], has been approved by the European Commission for the treatment of peanut allergy in the European … Read the full press release
Posted in European Union, Food & Beverage, Healthcare, News, Pharma & Biotech, Switzerland
Tagged Aimmune Therapeutics, Andrew Oxtoby, ARTEMIS, EC, EU, European Commission, European Union, food allergies, Greg Behar, Nestlé Health Science, OIT, oral desensitization therapy, oral immunotherapy, PALFORZIA, PALISADE, peanut allergy, peanut protein, SwissMedic, treatment of peanut allergy
(PRESS RELEASE) VEVEY, 14-Oct-2020 — /EuropaWire/ — Nestlé has successfully closed the acquisition of biopharmaceutical company, Aimmune Therapeutics, Inc. (Nasdaq: AIMT). The company which specializes in developing and bringing new treatments to people with potentially life-threatening food allergies joins Nestlé … Read the full press release
Posted in Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged acquisition, Aimmune Therapeutics, allergic reactions, allergies, AlMab7195, anaphylaxis, Andrew Oxtoby, Arachis hypogaea, asthma, EM, Eosinophilic Gastrointestinal Disease, European Medicines Agency, FDA, Greg Behar, monoclonal antibody, Nestlé, Nestlé Health Science, NHSc, oral immunotherapy, PALFORZIA®, Peanut Allergen Powder-dnfp, Pharmaceutical, science-bassed nutritional solutions, Swiss Agency for Therapeutic Products, SwissMedic, treating peanut allergy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
